Public Employees Retirement System of Ohio Acquires New Shares in Pharvaris (NASDAQ:PHVS)

Public Employees Retirement System of Ohio bought a new position in Pharvaris (NASDAQ:PHVS) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 3,100 shares of the company’s stock, valued at approximately $57,000.

A number of other hedge funds have also added to or reduced their stakes in PHVS. HighVista Strategies LLC boosted its position in shares of Pharvaris by 35.9% in the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock valued at $422,000 after acquiring an additional 6,018 shares during the period. Sofinnova Investments Inc. boosted its holdings in Pharvaris by 2.9% in the 2nd quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock valued at $11,309,000 after purchasing an additional 16,862 shares during the period. Jane Street Group LLC purchased a new position in shares of Pharvaris during the 3rd quarter valued at $526,000. Sphera Funds Management LTD. increased its holdings in shares of Pharvaris by 8.9% in the third quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock worth $8,136,000 after purchasing an additional 36,027 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Pharvaris in the third quarter worth $906,000.

Analysts Set New Price Targets

Separately, Oppenheimer boosted their target price on Pharvaris from $38.00 to $42.00 and gave the stock an “outperform” rating in a research report on Friday, September 6th.

Pharvaris Price Performance

PHVS stock opened at $19.57 on Monday. The firm has a 50 day simple moving average of $21.21 and a two-hundred day simple moving average of $19.25. The stock has a market cap of $623.11 million, a PE ratio of -6.99 and a beta of -3.17. Pharvaris has a one year low of $15.37 and a one year high of $33.00.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.